ArticleACS applied bio materials2026
Mg-Hydroxyapatite Nanorods for Dual Intracellular Doxorubicin Delivery and Osteogenic-Associated BM-MSC Responses.
Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracellular drug therapies are based on the use of nanocarriers that can successfully penetrate cell barriers and release therapeutic payloads directly inside the cell environment. In this context, hydroxyapatite (HA) nanoparticles provide a particularly promising platform owing to their inherent biocompatibility, bioactivity, and drug-binding capability. This work hence examines anisotropic HA nanorods (NRs), synthesized using hydrothermal methods, with a particular focus on Mg-to-Ca ion substitution, aiming to increase the bioactivity and improve the interaction with therapeutics, specifically targeting intracellular sustained release. Our findings indicate that increasing the extent of Mg doping in apatite NRs induces enhanced cell compatibility and interaction with primary human bone marrow-derived mesenchymal stem cells. Moreover, the doping with Mg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.